Best Hospitals for Oral Cancer Treatment in Bengaluru, India

Oral cancer refers to malignant neoplasms arising within the oral cavity, encompassing the lips, buccal mucosa, hard palate, anterior two-thirds of the tongue (oral tongue), floor of the mouth, upper and lower alveolar ridges, and retromolar trigone. Squamous cell carcinoma (SCC) accounts for approximately 90% of all oral cavity malignancies, with the remainder comprising mucoepidermoid carcinoma, adenoid cystic carcinoma, verrucous carcinoma, and rare sarcomatous or melanocytic variants. The disease exerts profound physiological consequences: tumour infiltration of the intrinsic tongue musculature, mandible, or floor-of-mouth disrupts mastication, deglutition, and articulation, while perineural invasion along the inferior alveolar or lingual nerves produces neuropathic pain and sensory deficits. Lymphatic spread to ipsilateral or bilateral cervical nodal basins (levels I–IV) is a critical prognostic determinant, and distant metastasis to lungs, liver, or bone portends a significantly diminished survival horizon.

• **Confirmed histopathological diagnosis**: Tissue biopsy (incisional or punch) with histological subtyping and grade is mandatory before any treatment planning.
• **Clinical staging workup**: Contrast-enhanced MRI of the primary site and neck (to assess depth of invasion, cortical bone involvement, and nodal characteristics), contrast-enhanced CT of chest/abdomen/pelvis or integrated PET-CT (18F-FDG) for distant metastasis staging, and orthopantomogram (OPG) or cone-beam CT when mandibular involvement is suspected.
• **Stage I–IVB oral cavity SCC**: Suitable for curative-intent treatment. Patients with resectable Stage I–II disease are optimal surgical candidates. Stage III–IVA patients may be candidates for composite resection with free-flap reconstruction or concurrent chemoradiation depending on surgical morbidity assessment.
• **Performance status**: ECOG Performance Status 0–2 preferred for aggressive multimodal therapy; ECOG 3 patients may be considered for palliative-intent radiation or single-agent systemic therapy.
• **Organ function thresholds**: Creatinine clearance ≥50 mL/min (for cisplatin eligibility), haemoglobin ≥10 g/dL, platelet count ≥100,000/µL, adequate hepatic function (AST/ALT <2.5× ULN).
• +4 more

- Unresectable Stage IVB disease with carotid encasement (relative; consider definitive CRT)

- Stage IVC (distant metastatic) disease: curative intent contraindicated; systemic therapy or best supportive care

**1. Surgical Resection — The Primary Curative Modality**

Surgical management is stratified by tumour site, size (T classification), depth of invasion (DOI), and mandibular proximity. Resection aims for a minimum 5 mm clear margin in all three dimensions.

• **Transoral Resection (TOR)**: Standard approach for accessible oral tongue, floor-of-mouth, and buccal lesions. Performed under general anaesthesia using cold-steel or electrosurgical techniques. Intraoperative frozen-section margin analysis is employed at high-volume centres.
• **Transoral Robotic Surgery (TORS)**: Although primarily established for oropharyngeal carcinoma, TORS (da Vinci Xi/SP platform) is increasingly applied to posterior oral tongue and retromolar trigone lesions, offering enhanced 3D visualisation, wristed instrument dexterity, and reduced thermal spread compared to conventional transoral laser microsurgery (TLM).
• **Mandibulotomy / Visor Flap Access**: Employed for posteriorly located tumours requiring wide access; involves a midline or paramedian mandibular osteotomy with subsequent rigid plate fixation.
• **Marginal Mandibulectomy**: Resection of the alveolar rim while preserving mandibular continuity; appropriate when tumour abuts but does not radiologically invade the cortical bone.
• **Segmental Mandibulectomy**: En bloc resection of a mandibular segment including tumour; mandates immediate vascularised bony reconstruction.
• **Maxillectomy (Infrastructure / Total)**: For hard palate and upper alveolar primaries; infrastructure maxillectomy preserves the orbital floor, while total maxillectomy includes the orbital floor when involved.

**2. Cervical Lymph Node Management**

**Phase 1: Pre-Arrival & Remote Consultation (Weeks 1–2)**

• Patient submits medical records, biopsy pathology report, imaging (MRI/CT/PET-CT), and blood investigations to GAF Healthcare's clinical coordination team.
• GAF Healthcare's oncology panel—comprising head-and-neck surgical oncologists, radiation oncologists, and medical oncologists—conducts a multidisciplinary tumour board (MDT) review and issues a detailed treatment plan with itemised cost estimate within 48–72 hours.
• Visa facilitation initiated: e-Medical Visa (India) or visa-on-arrival/prior arrangement (UAE) processed concurrently.
• Pre-travel optimisation: nutritional supplementation commenced, dental extractions (if indicated pre-radiation) coordinated locally, and PEG tube insertion scheduled at the destination centre if DOI and swallowing compromise suggest post-operative feeding requirement.

**Phase 2: Arrival & Pre-Treatment Assessment (Days 1–5)**